Eli Lilly and Company discovers ... Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as ...

The heads of The RMR Group, Lupoli Cos. and National Development share their investment and development priorities for 2025.

The team that brought you Karuna – recently sold to Bristol-Myers Squibb for $14 billion – has set up a neuropsychiatry-focused biotech called Seaport ... of R&D at Eli Lilly before moving ...

The new Seaport spot is the first location in Boston. It opened in early January. PopUp Bagels describes its start as a “backyard pickup window to share a newly created bagel recipe with friends.” ...

Seaport and the Wharf District are two of the most popular neighborhoods in Boston. The Seaport continues to be the up-and-coming neighborhood in the city, and the Wharf District is home to ...

Over the past six months, Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the ...

Eli Lilly and Co., which cemented its place in Boston last year with the opening of a new research and development center, is now buying a cancer program from a Boston biotech. Eli Lilly and Co ...

Shares of Eli Lilly have been falling in recent months, but that could spell opportunity. Investors appear to be concerned that a new government could impact its growth potential. The business is ...

Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday at $785.41. Meacham covers the Healthcare sector ...

Eli Lilly's GLP-1 market dominance, supported by superior efficacy and strong manufacturing investments, positions it as a leader alongside Novo Nordisk, with forecasted revenue growth to $75B by ...

Eli Lilly's small pop was due to the latest developments in the lab reported by Novo Nordisk (NYSE: NVO), which, like the U.S. company, is doing brisk business with a weight loss drug: Wegovy ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price target of $950.00. David Risinger has given his Buy rating ...